Brief: Ryvu Therapeutics Says That BioNTech Terminated STING Program
January 30 (Reuters) - Ryvu Therapeutics SA RVU.WA :
* SAID ON WEDNESDAY THAT BIONTECH HAS TERMINATED "STING"
PROGRAM
AND TWO OTHER PROGRAMS
* AFTER TERMINATION RYVU THERAPEUTICS TO REGAIN FULL RIGHTS
TO THE
PROGRAM
* BIONTECH TO FINANCE ALL R&D COSTS IN ONGOING COLLABORATION
WITH
RYVU
Source text: urn:newsml:reuters.com:*:nEM4wdVJda
Further company coverage: RVU.WA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys